Recently a small molecular compound AMG 510, which inhibits RAS activity by directly targeting KRAS G12C, broke the dilemma of CRC patients bearing RAS mutations.[16,20–22] KRAS G12C, a new star mutation, occurs in 3% of the CRC population in a published study.[23] Our study indicated that the accurate frequency of KRAS G12C in China is slightly lower (2.2%) than in Western countries. Here, KRAS is linked to colorectal carcinoma.